RxDoctor Payments Data

David Narotsky, MD

Cardiovascular Disease · Fairfield, CTNPI 1831469832

Payments from drug & device makers

$525in general payments, 2019–2025

Across 9 payments — averaging $58.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$163
  • AstraZeneca$129
  • Johnson & Johnson$125
  • Braemar Manufacturing, LLC$55
  • Pfizer$29
  • E.r. Squibb & Sons, L.L.C.$25

What the payments were for

  • Food & beverage$525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$163
AstraZeneca1$129
Johnson & Johnson1$125
Braemar Manufacturing, LLC1$55
Pfizer2$29
E.r. Squibb & Sons, L.L.C.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525 in reported general payments places this provider in the 30th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$268,524
Medicare patients
1,180
Services billed
3,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$505,774
VyndamaxTafamidis12$269,336
XareltoRivaroxaban165$237,958
Repatha SureclickEvolocumab86$76,702
EntrestoSacubitril/Valsartan36$56,146
FarxigaDapagliflozin Propanediol29$33,437
Praluent PenAlirocumab29$17,910
VascepaIcosapent Ethyl17$15,225
JardianceEmpagliflozin14$14,192
Metoprolol Succinate738$10,737
Rosuvastatin Calcium743$9,518
Atorvastatin Calcium519$6,826
Ezetimibe198$4,622
Amlodipine Besylate555$4,604
Losartan Potassium387$3,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$29$775,111391 claims
Johnson & JohnsonXarelto$125$237,958165 claims
AstraZenecaFarxiga$129$33,43729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →